🇺🇸 FDA
Pipeline program

LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

IM027068

Phase 3 small_molecule active

Quick answer

LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278 for Idiopathic pulmonary fibrosis is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Idiopathic pulmonary fibrosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials